A carregar...
Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as a standard therapy have been used in EGFR-mutated adenocarcinoma of non-small-cell lung cancer (NSCLC) patients in recent years. But in current randomized prospective clinical trials, due to few cases of non-adenocarcinoma...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5488763/ https://ncbi.nlm.nih.gov/pubmed/28790845 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S134523 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|